Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men.
The aging of the human immunodeficiency virus type 1 (HIV-1)-infected population obligates a focus on the interaction between aging, comorbid conditions, and HIV-1. We recruited a cohort of HIV-1-infected men aged ≤ 35 years or ≥ 50 years who were receiving fully suppressive antiretroviral therapy (ART). We analyzed plasma markers of inflammation; T-cell activation, exhaustion, proliferation; and innate cellular subsets and functional capacity. Levels of lipopolysaccharide and the plasma marker of chemokine (C-C motif) ligand 2 were significantly elevated in older HIV-infected men despite comparable cellular phenotypes. Compared with similarly age-stratified uninfected subjects, older HIV-1-infected adults were also more frequently in the upper quartile of soluble CD14 expression.
Ragon Institute of MGH, MIT, and Harvard, Cambridge Division of Infectious Diseases, Brigham and Women's Hospital.
Eileen
E
Scully
Ragon Institute of MGH, MIT, and Harvard, Cambridge.
Ainsley
A
Lockhart
Division of Infectious Diseases, Massachusetts General Hospital.
Lisa
L
Huang
Division of Infectious Diseases, Brigham and Women's Hospital.
Yvonne
Y
Robles
Division of Infectious Diseases, Massachusetts General Hospital.
Carlos
C
Becerril
Ragon Institute of MGH, MIT, and Harvard, Cambridge.
Marisol
M
Romero-Tejeda
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School.
Mary A
MA
Albrecht
Ragon Institute of MGH, MIT, and Harvard, Cambridge.
Christine D
CD
Palmer
Harvard School of Public Health, Boston, Massachusetts.
Ronald J
RJ
Bosch
Ragon Institute of MGH, MIT, and Harvard, Cambridge Heinrich-Pette-Institut, Hamburg, Germany.
Marcus
M
Altfeld
Division of Infectious Diseases, Brigham and Women's Hospital.
Daniel R
DR
Kuritzkes
Division of Infectious Diseases, Boston Medical Center, Boston University School of Medicine, Massachusetts.
Nina H
NH
Lin
D000328:Adult; D000375:Aging; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018988:Bacterial Translocation / Q000502:physiology*; D015415:Biomarkers; D018932:Chemokine CCL2 / Q000235:genetics / Q000378:metabolism*; D005838:Genotype; D015658:HIV Infections / Q000378:metabolism* / Q000821:virology; D015497:HIV-1; D006801:Humans; D007113:Immunity, Innate / Q000502:physiology; D007249:Inflammation / Q000378:metabolism; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000502:physiology
D019380:Anti-HIV Agents; D015415:Biomarkers; C111835:CCL2 protein, human; D018932:Chemokine CCL2
HIV-1; chemokine; inflammation; monocytes